Beranda › Kanker Hati › Texas
Uji klinis Kanker Hati di Texas
24 studi untuk Kanker Hati mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
DESTINY-PANTUMOUR04
- Research Site, Dallas
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000National Liver Cancer Screening Trial
- UT Southwestern Medical Center and Parkland Hospital, Dallas
- Baylor College of Medicine, Houston
Menerima pesertaFase 4
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06084234CREO - Microwave Ablation Feasibility Study
- Memorial Hermann-Texas Medical Center, Houston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07817147Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- St. David's Medical Center, Austin
Menerima pesertaStudi observasional
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04864054A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- UT MD Anderson, Houston
- NEXT Oncology, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06440005Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT04715191Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
- MD Anderson Cancer Center, Houston
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07010315Multi-analyte Blood Test Clinical Trial
- South Texas Research Institute, Edinburg
- Texas Gastro Research, El Paso
- Impact Research Institute, Waco
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT05199259A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- NEXT Dallas, Dallas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07337525Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT07327489A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
- Clinical Trial Site, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Menerima peserta
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT05486572Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Dallas, Fort Worth
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07517198Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06362369The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Md Anderson Cancer Center, Houston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT04075305Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Baylor College of Medicine, Houston
Menerima pesertaFase 2
Usia 0 hingga 30 · Semua jenis kelamin · Diperbarui 24 Feb 2026 · NCT04134559A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- NEXT Dallas, Dallas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Jan 2026 · NCT07317505Sample Collection for Ongoing Research and Product Evaluation Study
- Natera, Inc., Austin
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jan 2026 · NCT07318051SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774EGCG for Hepatocellular Carcinoma Chemoprevention
- UT Southwestern, Dallas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Sep 2025 · NCT06015022Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- Site 881, Dallas
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Apr 2025 · NCT05201404Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
- Houston Methodist Research Institute, Houston
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Feb 2023 · NCT05185505Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.